glp-1 and gip dual agonist Major physiological roles of GIP. Tirzepatide is acting as an Cardiorenal Outcomes With GLP-1 vs.
Description
doi: 10.3803/EnM.2019.34.3.247
February 2025: Novo Nordisk announced that semaglutide 2.4 mg would be available in Mexican pharmacies by April 2025, with an average 17.5% weight loss observed in pivotal trials

12,13 As evidence of our concern about patients taking GLP-1 receptor agonists, we identified a recent case report that described a patient taking semaglutide who experienced an aspiration event with food remains during induction of anesthesia despite having fasted for 18 hours

Davies MJ, Bergenstal R, Bode B, et al

Please see Full Prescribing Information, including Medication Guide, for CONTRAVE
